William Delaney

William Delaney, PhD joined Assembly as Chief Scientific Officer in 2020.  Prior to joining Assembly, he held positions of increasing responsibility over a 20  year period at Gilead Sciences, serving most recently as an Executive Director in the Biology department. While at Gilead, he lead the Viral Hepatitis & Herpes Discovery Biology Group, served as the Research Therapeutic Area Head for HBV, and contributed to the development of several marketed products, including Hepsera®, Viread®, and Vemlidy® for HBV and Sovaldi®, Harvoni®, Epclusa®, and Vosevi® for HCV.  He earned a BS in Biotechnology from the University of Delaware and a PhD in Cell and Molecular Biology from the Penn State College of Medicine. In addition, he completed a Postdoctoral Fellowship at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Department of Research & Molecular Development.